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Robert J. Applegate, MDSEE PAGE 281I ntracoronary stent therapy for obstructive coro-nary atherosclerosis has come a long way sincethe ﬁrst stent was developed in the 1980s.
Although balloon angioplasty allowed percutaneous
revascularization with a high degree of success, acute
complications including ﬂow-limiting dissections
occurred frequently enough to stimulate research
into more secure scaffolding to preserve the luminal
enlargement created by balloon dilation. Metallic
stents almost completely eliminated the acute
complications of balloon dilation, but unwittingly
stimulated a vascular response that included a prolif-
erative intimal response in almost one-fourth to one-
third of stented patients. This clinical limitation of
metallic stents stimulated tremendous research into
the biology of vascular injury, resulting in recognition
of the role of “tor” (target of rapamycin) that served
as the site of action of the antiproliferative agent siro-
limus, the ﬁrst drug used in the now historical ﬁrst-
generation sirolimus-eluting stent (SES), Cypher.
Once again, SES achieved the almost complete sup-
pression of neointimal hyperplasia, but at the
expense of altering normal vascular healing and stim-
ulating inﬂammatory changes with enhanced throm-
bogenicity in a minority of patients. The current
generation of drug-eluting stents (DES) changed
each of the components of the drug-eluting system:
lower drug dose with a more efﬁcacious release
pattern, thinner metallic struts, and more biologically
compatible polymers to store and release the drugs.
The clinical efﬁcacy and safety of these newer stent*Editorials published in JACC: Cardiovascular Interventions reﬂect the
views of the authors and do not necessarily represent the views of JACC:
Cardiovascular Interventions or the American College of Cardiology.
From the Section of Cardiovascular Medicine, Wake Forest School of
Medicine, Winston-Salem, North Carolina. Dr. Applegate is a consultant
for and on the Advisory Board of Abbott Vascular.systems have been demonstrated in multiple clinical
trials.
Despite the clinical success of the current genera-
tion of DES, the pathway to their development as
outlined above highlights some of the challenges and
limitations of the scientiﬁc foundation on which
percutaneous mechanical treatment of obstructive
coronary disease is based. The desire to improve
these therapies has driven research into many diverse
ﬁelds relevant to stent therapy including vascular
responses to injury, thrombosis, biochemistry, poly-
mer chemistry, and metallurgy. Given the complexity
of the biological processes occurring in an athero-
sclerotic vessel, not to mention the vascular response
occurring after stent therapy, it is not surprising that
animal models precisely mimicking events in humans
have been difﬁcult to develop and validate. The
relative paucity of animal models allowing precise,
systematic analysis of biological processes is reﬂected
in the clinical history of stent therapy development
and makes reﬁnement of current generation of stents
challenging. Nonetheless, animal models have been
useful in evaluating certain aspects of the biological
response to injury of a coronary artery such as occurs
with placement of a DES.In this issue of JACC: Cardiovascular Interventions,
Nishimiya et al. (1) address the issue of the role of the
polymer coating of a DES in the inﬂammatory
response to its presence, as well as the potential
abnormal vasoconstrictive responses observed in the
presence of the DES. The inﬂammatory and throm-
botic responses after ﬁrst-generation DES in autopsy
series have been well documented by Virmani et al.
(2). However, the causative agent could not be
delineated from these studies. Nishimiya and col-
leagues (1) also highlight a growing body of recent
literature that identiﬁes an incidence of angina in up
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293to one-fourth of patients with a successful DES pro-
cedure, as well as abnormal vasoconstrictive re-
sponses in certain types of DES. Moreover, there are
scattered reports of a higher incidence of stent
thromboses in patients with an abnormal vasocon-
strictive response after DES placement. To this point,
it is not known what portion of a DES is responsible
for the abnormal coronary vasomotion, although
limited data suggest that the polymer coating may
play an important role. Using a porcine model, the
authors randomly implanted 4 types of stents in the
left anterior descending and left circumﬂex coronary
arteries: a polylactic acid (PLA)–polymer coated stent
that degrades in 6 to 9 months with sirolimus (PþDþ);
a PLA polymer–coated stent without sirolimus
(PþD); a novel poly-DL-lactic acid and poly-
caprolactone (PDLLA-PCL) copolymer–coated stent
that degrades in 3 months; and the same bare metal
stent (BMS) without polymer or drug.
Both PþDþ and PþD were associated with signif-
icantly more inﬂammation at both the proximal and
distal ends of the stents, as well as serotonin-
stimulated vasoconstrictive responses than either
PDLLA-PCL stent or the BMS. The authors next eval-
uated whether the vasoconstrictive responses to se-
rotonin were ameliorated by a speciﬁc Rho kinase
inhibitor, fasupril. Fasupril completely abolished the
vasoconstrictive responses to serotonin, conﬁrming
that Rho kinase activation and signaling pathway
were responsible for the abnormal vasomotion. These
ﬁndings provide valuable insights into the role of the
individual components of stent drug delivery systems
in inﬂammation as well as abnormal vasoconstrictive
responses. As clinical practice moves toward adoption
of stent therapies with bioabsorbable polymers and/or
completely bioresorbable stents scaffolds, these data
should be valuable in the development of the most
efﬁcacious and safe drug delivery systems possible.
The Rho kinase signaling pathway has been impli-
cated in a wide array of biological processes including
inﬂammation, thrombosis, and vasomotion (3). It also
contributes to the pleiotropic effect of statins. Speciﬁc
Rho kinase inhibitors have been developed and used
in limited clinical trials with patients (4). They have
been shown to substantially reduce angina in patients
refractory to traditional therapies. Although it still
remains speculative whether speciﬁc Rho kinase in-
hibitors could be clinically useful in patients withpersistent angina after successful DES implantation,
the data from the current study make it appealing to
consider this as a possible therapeutic target.
As alluded to earlier in this editorial, it is often
difﬁcult to track mechanisms responsible for a bio-
logical response in a single experiment or model. In
this case, the authors acknowledge important consid-
erations that will need to be addressed to generalize
these observations beyond the current experimental
model. The authors speciﬁcally chose a thick strutted
stent model to isolate the effects of the polymer and
the drug delivery. Yet today, based on experimental
and clinical data showing that thin strutted metallic
stents evoked less inﬂammation than thicker strutted
metallic stents, these stents are no longer clinically
used (5). Thus, the impact of thin strutted stents on the
observations from this study remains to be deter-
mined. Additionally, the authors did not evaluate the
impact of durable polymers such as the ﬂuoropolymer
in the everolimus-eluting stent that has been shown in
animal models to evoke little inﬂammation (6).
The ﬁnal pieces of information that remain pro-
vocative from this study are the observations sur-
rounding the enhanced vasoconstrictive responses to
serotonin, and their amelioration by the speciﬁc Rho
kinase inhibitor fasudil, in the PþDþ stents. An in-
terest in the role of vasospasm in the causation of
myocardial infarction as well as a distinct mechanism
for angina in certain patients spurred animal and
experimental investigation into vasospasm as well as
spasmolytic agents. As the mechanism of myocardial
infarction became more clearly elucidated and the
importance of vasospasm as a clinical entity faded,
vasospasm as an important therapeutic target all
but faded from clinical investigation. Interest in
abnormal vasoconstrictive responses has once again
arisen as several different clinical observations point
toward an important clinical role for abnormal vaso-
motion after placement of current-generation stents
(7). Although the ﬁnal chapter(s) in this story remains
to be told, Nishimiya et al. (1) have provided a small
but important piece of the puzzle.
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